Score Overview
Explore the 2021 public Archive ranking →
Where Celldex Therapeutics Inc has ranked, year by year
Showing 10 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- CLDX
2019: 98.4% · 2021: 99.9% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-10-22 | $ 28.97 | — |
1 Year2025-10-22 | $ 26.72 | 8.42% |
5 Years2021-10-22 | $ 47.39 | -38.87% |
10 Years2016-10-21 | $ 50.10 | -42.18% |
20 Years2006-10-20 | $ 279.00 | -89.62% |
30 Years1996-10-22 | $ 360.00 | -91.95% |
All Time2008-03-10 | $ 114.45 | -74.69% |
| Period | Last Price2026-10-22 | 1 Year2025-10-22 | 5 Years2021-10-22 | 10 Years2016-10-21 | 20 Years2006-10-20 | 30 Years1996-10-22 | All Time2008-03-10 |
|---|---|---|---|---|---|---|---|
| Price | $ 28.97 | $ 26.72 | $ 47.39 | $ 50.10 | $ 279.00 | $ 360.00 | $ 114.45 |
| Return | — | 8.42% | -38.87% | -42.18% | -89.62% | -91.95% | -74.69% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 112K | -$ 300M | $ 717M |
| 2025 | $ 1M | -$ 258M | $ 518M |
| 2024 | $ 7M | -$ 157M | $ 725M |
| 2023 | $ 6M | -$ 141M | $ 421M |
| 2022 | $ 2M | -$ 112M | $ 304M |
| 2021 | $ 4M | -$ 70M | $ 408M |
| 2020 | $ 7M | -$ 59M | $ 194M |
| 2019 | $ 3M | -$ 50M | $ 64M |
| 2018 | $ 9M | -$ 151M | $ 94M |
| 2017 | $ 12M | -$ 93M | $ 139M |
| 2016 | $ 6M | -$ 128M | $ 189M |
| 2015 | $ 5M | -$ 127M | $ 289M |
| 2014 | $ 3M | -$ 118M | $ 201M |
| 2013 | $ 4M | -$ 81M | $ 302M |
| 2012 | $ 11M | -$ 59M | $ 83M |
| 2011 | $ 9M | -$ 44M | $ 53M |
| 2010 | $ 46M | -$ 2M | $ 61M |
| 2009 | $ 15M | -$ 36M | $ 82M |
| IPO2008 | $ 7M | -$ 47M | $ 44M |
Celldex Therapeutics Inc fundamental performance
Between 2015 and 2025, revenue declined from $ 5M to $ 1M and net income went from -$ 127M to -$ 258M. Revenue increased in 4 of those 10 years; net income in 2.
Across Celldex Therapeutics Inc's full reported history, from 2008 to 2025, revenue declined from $ 7M to $ 1M and net income went from -$ 47M to -$ 258M. Revenue increased in 50% of the years measured; net income in 22%.
Celldex Therapeutics Inc currently holds a 5-year HDB Score of 1.0 out of 10. How the HDB Score is calculated.
Membership
Continue CLDX’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 5,119 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
